Daniel K. Baeschlin

Daniel K. Baeschlin

Auto-generated profile, based on publicly available information

Daniel K. Baeschlin

Novartis Institutes for BioMedical Research, Novartis Campus, CH-4002 Basel, Switzerland

Research Focus & Metrics

Academic Career Length

19Years (2008-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
3 November 2020 in Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
ASAnsgar Schuffenhauer
Ansgar Schuffenhauer
NSNadine Schneider
Nadine Schneider
SHSamuel Hintermann
Samuel Hintermann
DADouglas Auld
Douglas Auld
JBJutta Blank
Jutta Blank
DBDaniel K. Baeschlin
Daniel K. Baeschlin

14 October 2008 in The Journal of Organic Chemistry
Verified
Journal Article
Closed access
ZFZhongbo Fei
Zhongbo Fei
QWQuanbing Wu
Quanbing Wu
FZFei Zhang
Fei Zhang
YCYudong Cao
Yudong Cao
CLChuanqin Liu
Chuanqin Liu
KNKenji Namoto
Kenji Namoto

13 September 2026 in bioRxiv
Verified
Preprint
Open access
PDF file
LSLeonie Seefeldt
Leonie Seefeldt
CGChristin Gumpp
Christin Gumpp
OCOlivia Carril
Olivia Carril
JEJerome Eberhardt
Jerome Eberhardt
SBSylwia Boltryk
Sylwia Boltryk
NBNicolas M B Brancucci
Nicolas M B Brancucci
Most antimalarials are ineffective against the sexual transmission stages, known as gametocytes, of the malaria parasite Plasmodium falciparum . Their low sensitivity to drugs is attributed to limited compound uptake and a poorly understood form of cellular quiescence. Our current understanding of druggable transmission-blocking processes is therefore limited. Based on genetically engineered parasites that facilitate the mass production of synchronous mature gametocytes, we developed a high throughput drug screening platform that allowed us to test more than 50,000 compounds for gametocytocidal effects in one day. By screening a diversity-oriented library, we identified over 40 molecules that kill mature gametocytes in the low nanomolar range. Using resistance selection coupled to whole genome sequencing and drug-target interaction modelling, we followed up on three chemically tractable compounds that are also highly active against asexual parasites and prevent gametocyte transmission to mosquitoes. We show that the compound ONX-0914, a specific inhibitor of the β5i/LMP7 subunit of human immunoproteasomes, targets the parasite proteasomal β5 subunit. In contrast, the compounds CR-1-31-B and brusatol interfere with translation by targeting eukaryotic initiation factor 4A (eIF4A) and the peptidyl transferase center (PTC) of the 80S ribosome, respectively. Interestingly, parasite resistance to brusatol, a broad-spectrum antitumor drug, is linked to the differential modification of specific rRNA bases near the ribosomal A-site, mediated by altered base specificity of a rRNA methyltransferase. In summary, we successfully combined high-throughput compound screening with drug target deconvolution to reveal the targets and mode-of-action for three potent gametocytocidal molecules and discover the mechanism of resistance to the anti-tumorigenic drug brusatol. In addition to critically advancing our understanding of mature gametocyte biology and druggable processes in P. falciparum transmission stages, our observations made with brusatol-resistant parasites may become relevant for anti-cancer drug research.